Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 3/20 | 0.44 |
| ▸ | BRD4 | O60885 | 2/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | RHOA | P61586 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776108 | 0.90 | CREBBP (0.45) | CREBBPBRD4BRAFCNR1RHOA | |
| SCHEMBL16775982 | 0.87 | CACNA1G (0.43) | BRAFTHRBATR | |
| SCHEMBL16776407 | 0.87 | CREBBP (0.44) | CREBBPBRD4BRAFRHOAIMPDH2 | |
| SCHEMBL19670170 | 0.84 | BRAF (0.40) | CREBBPBRD4BRAFCNR1THRB | |
| SCHEMBL16776052 | 0.84 | CREBBP (0.43) | CREBBPBRD4BRAFCNR1RHOA | |
| SCHEMBL16775983 | 0.83 | HDAC2 (0.39) | OPRM1OPRD1MTORATR | |
| SCHEMBL16776422 | 0.83 | CREBBP (0.40) | CREBBPBRD4BRAFRHOA | |
| SCHEMBL16775989 | 0.83 | RPS6KA3 (0.41) | LRRK2OPRM1OPRD1MTORATR | |
| SCHEMBL16776410 | 0.82 | CREBBP (0.38) | CREBBPBRD4BRAFRHOAIMPDH2 | |
| SCHEMBL16775991 | 0.82 | THRB (0.39) | THRBLRRK2MTORATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | CREBBP 528/4885BRD4 180/4885BRAF 3419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.